A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

Recruiting now · Phase 2

Conditions studied: Autoimmune Bullous Disease

In brief

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease

Key facts

Study ID

NCT06900010

Run by

Shandong First Medical University

People needed

30

Starts

2025-04-22

Expected to finish

2028-01-01

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Confirmed diagnosis of autoimmune bullous disease；
• 2. Age ≥18 years, regardless of gender；
• 3. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.

You may not qualify if…

• 1. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation；
• 2. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；
• 3. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；
• 4. Any other condition deemed by the investigator to render the subject unsuitable for study participation.

Where it is running

• Dermatology Hospital Affiliated to Shandong First Medical University — Jinan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.